Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Sponsored by Novartis Pharmaceuticals
About this trial
Last updated 3 years ago
Study ID
CLJC242A2201J
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 5 years ago
What is this trial about?
The purpose of this study was to assess the safety, tolerability, and efficacy of a
combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with
nonalcoholic steatohepatitis (NASH) and liver fibrosis.
What are the participation requirements?
Inclusion Criteria